

# **Market Announcement**

22 February 2024

## INOVIQ Ltd (ASX: IIQ) - Trading Halt

### **Description**

The securities of INOVIQ Ltd ('IIQ') will be placed in trading halt at the request of IIQ, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 23 February 2024 or when the announcement is released to the market.

#### **Issued by**

**ASX Compliance** 



#### 22 February 2024

By email: tradinghaltsmelbourne@asx.com.au

Melissa Kostopoulos Compliance Adviser Listings Compliance (Melbourne) Australian Securities Exchange

Dear Melissa

#### INOVIQ Limited (ASX Code: IIQ) - Request for trading halt

Pursuant to ASX listing rule 17.1, INOVIQ Limited ACN 009 070 384 (**Company**) requests an immediate trading halt be granted by the ASX in respect of the Company's securities prior to the commencement of trading on Thursday, 22 February 2024 as the Company finalises its report related to its Breast Cancer Monitoring Study.

In accordance with ASX listing rule 17.1, the Company provides the following information:

- (a) the Company is seeking the trading halt pending an announcement in relation to the results of its Breast Cancer Monitoring Study;
- (b) the Company requests that the trading halt last until the earlier of the Company releasing an announcement in relation to the study, or until the commencement of trading on Friday, 23 February 2024;
- (c) the Company anticipates that the trading halt will cease on it making the announcement in relation to the results of its Breast Cancer Monitoring Study;
- (d) the Company is not aware of any reason why the trading halt should not be granted; and
- (e) the Company is not aware of any further information which needs to be disclosed to the market at the time of seeking the trading halt.

If you have any queries, please contact me.

7268

Yours faithfully

Mark Edwards

Chief Financial Officer and Company Secretary

**INOVIQ Limited** 

Ph: (03) 9548 7586

This document is authorised for release by the Board of Directors.